Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

News
ABFM C-MTX Regimen Shows Promise in Newly Diagnosed T-cell Lymphoblastic Lymphoma
07/31/2020
The ABFM regimen with C-MTX yielded excellent outcomes in a study of patients with newly diagnosed T-cell lymphoblastic lymphoma.
The ABFM regimen with C-MTX yielded excellent outcomes in a study of patients with newly diagnosed T-cell lymphoblastic lymphoma.
The ABFM regimen with C-MTX...
07/31/2020
Oncology
News
FDA Approves Pembrolizumab for Certain Adults, Pediatric Patients With TMB-H Solid Tumors
06/17/2020
The FDA has approved pembrolizumab for the treatment of certain adult and pediatric patients with unresectable or metastatic TMB-H solid tumors.
The FDA has approved pembrolizumab for the treatment of certain adult and pediatric patients with unresectable or metastatic TMB-H solid tumors.
The FDA has approved...
06/17/2020
Oncology
News
FDA Approves Gemtuzumab Ozogamicin for Certain Patients With AML
06/16/2020
The FDA extended the indication of gemtuzumab ozogamicin to include newly diagnosed CD33-positive AML in patients aged 1 month and older.
The FDA extended the indication of gemtuzumab ozogamicin to include newly diagnosed CD33-positive AML in patients aged 1 month and older.
The FDA extended the indication...
06/16/2020
Oncology
News
Worse OS Tied to Pathologic Fractures in Adults With Extremity Osteosarcomas
03/09/2020
Among individuals with extremity osteosarcomas, investigators found a correlation between pathologic fractures and inferior OS in adult vs pediatric patients.
Among individuals with extremity osteosarcomas, investigators found a correlation between pathologic fractures and inferior OS in adult vs pediatric patients.
Among individuals with extremity...
03/09/2020
Oncology
News
Larotrectinib a Practical Therapy Option for TRK Fusion–Positive Solid Tumors
03/09/2020
Study findings show that long-term larotrectinib is feasible for use in the treatment of patients with advanced TRK fusion–positive solid tumors.
Study findings show that long-term larotrectinib is feasible for use in the treatment of patients with advanced TRK fusion–positive solid tumors.
Study findings show that...
03/09/2020
Oncology
News
Adding Decitabine–Vorinostat to Chemo Not Feasible for Relapsed ALL
01/29/2020
Despite yielding encouraging response rates, adding decitabine and vorinostat to chemo is not feasible for relapsed or refractory B-ALL because of a high incidence of significant toxicities.
Despite yielding encouraging response rates, adding decitabine and vorinostat to chemo is not feasible for relapsed or refractory B-ALL because of a high incidence of significant toxicities.
Despite yielding encouraging...
01/29/2020
Oncology
News
FDA Grants Accelerated Approval to First Therapy for Epithelioid Sarcoma
01/24/2020
The FDA has approved tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma ineligible for complete resection.
The FDA has approved tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma ineligible for complete resection.
The FDA has approved...
01/24/2020
Oncology
News
Nilotinib Therapy Safe, Effective for Certain Patients With CML
01/16/2020
Results from a phase 2 study demonstrate the efficacy and manageable safety of nilotinib for the treatment of pediatric patients with Ph-positive CML in chronic phase.
Results from a phase 2 study demonstrate the efficacy and manageable safety of nilotinib for the treatment of pediatric patients with Ph-positive CML in chronic phase.
Results from a phase 2 study...
01/16/2020
Oncology
Interview
Postsurgery Radiation Increases Survival in Pediatric Patients With Ependymoma
04/24/2019
Thomas Merchant, DO, PhD, discusses the use of postoperative radiation in pediatric patients with ependymoma.
Thomas Merchant, DO, PhD, discusses the use of postoperative radiation in pediatric patients with ependymoma.
Thomas Merchant, DO, PhD,...
04/24/2019
Oncology
Commentary
FDA Grants Expanded Approval of Treatment for Pediatric Patients With CML
03/22/2018
The US Food and Drug Administration has granted approval for a drug to include treatment of first- and second-line pediatric patients with chronic myeloid leukemia.
The US Food and Drug Administration has granted approval for a drug to include treatment of first- and second-line pediatric patients with chronic myeloid leukemia.
The US Food and Drug...
03/22/2018
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
ABFM C-MTX Regimen Shows Promise in Newly Diagnosed T-cell Lymphoblastic Lymphoma
07/31/2020
The ABFM regimen with C-MTX yielded excellent outcomes in a study of patients with newly diagnosed T-cell lymphoblastic lymphoma.
The ABFM regimen with C-MTX yielded excellent outcomes in a study of patients with newly diagnosed T-cell lymphoblastic lymphoma.
The ABFM regimen with C-MTX...
07/31/2020
Oncology
News
FDA Approves Pembrolizumab for Certain Adults, Pediatric Patients With TMB-H Solid Tumors
06/17/2020
The FDA has approved pembrolizumab for the treatment of certain adult and pediatric patients with unresectable or metastatic TMB-H solid tumors.
The FDA has approved pembrolizumab for the treatment of certain adult and pediatric patients with unresectable or metastatic TMB-H solid tumors.
The FDA has approved...
06/17/2020
Oncology
News
FDA Approves Gemtuzumab Ozogamicin for Certain Patients With AML
06/16/2020
The FDA extended the indication of gemtuzumab ozogamicin to include newly diagnosed CD33-positive AML in patients aged 1 month and older.
The FDA extended the indication of gemtuzumab ozogamicin to include newly diagnosed CD33-positive AML in patients aged 1 month and older.
The FDA extended the indication...
06/16/2020
Oncology
News
Worse OS Tied to Pathologic Fractures in Adults With Extremity Osteosarcomas
03/09/2020
Among individuals with extremity osteosarcomas, investigators found a correlation between pathologic fractures and inferior OS in adult vs pediatric patients.
Among individuals with extremity osteosarcomas, investigators found a correlation between pathologic fractures and inferior OS in adult vs pediatric patients.
Among individuals with extremity...
03/09/2020
Oncology
News
Larotrectinib a Practical Therapy Option for TRK Fusion–Positive Solid Tumors
03/09/2020
Study findings show that long-term larotrectinib is feasible for use in the treatment of patients with advanced TRK fusion–positive solid tumors.
Study findings show that long-term larotrectinib is feasible for use in the treatment of patients with advanced TRK fusion–positive solid tumors.
Study findings show that...
03/09/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement